Market Place
Sourcing Support
Adverum Biotech Inducement Grants Under Nasdaq LR 5635(c)(4)
06 Dec 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq
20 Nov 2024 //
GLOBENEWSWIRE
Adverum Presents Positive LUNA & OPTIC Results, Program Design
18 Nov 2024 //
GLOBENEWSWIRE
Adverum Biotech to Report 52-Week LUNA & OPTIC Data, Pivotal Plans
15 Nov 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports Q3 2024 Results and Milestones
04 Nov 2024 //
GLOBENEWSWIRE
Adverum Appoints Jason L. Mitchell As Chief Commercial Officer
16 Oct 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq
05 Sep 2024 //
GLOBENEWSWIRE
Adverum Biotech to Participate in Upcoming Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Wet AMD Gene Therapy Could Reach Millions
03 Sep 2024 //
BIOSPACE
Adverum Reports Q2 2024 Results And Provides Corporate Highlights
12 Aug 2024 //
GLOBENEWSWIRE
Adverum To Participate In H.C. Wainwright Ophthalmology Conference
02 Aug 2024 //
GLOBENEWSWIRE
Adverum`s Ixo-vec Granted FDA RMAT Designation For Wet AMD
01 Aug 2024 //
GLOBENEWSWIRE
Adverum Presents Positive Ixo-vec Data At ASRS Meeting
17 Jul 2024 //
GLOBENEWSWIRE
Adverum To Host Webcast On LUNA Phase 2 Wet AMD Trial Data From ASRS
10 Jul 2024 //
GLOBENEWSWIRE
Adverum To Participate In TD Cowen’s Genetic Medicines Summit
18 Jun 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as CMO
11 Jun 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies Q1 2024 Financials And Pipeline Highlights
09 May 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
03 May 2024 //
GLOBENEWSWIRE
Adverum Presents LUNA 26-Week Interim Analysis at ASRS
25 Apr 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports4Q FYR 2023 & Provides Pipeline Highlights
18 Mar 2024 //
GLOBENEWSWIRE
Adverum Reports Fourth Quarter and Full Year 2023 Financial Results
18 Mar 2024 //
GLOBENEWSWIRE
Adverum Bio to Participate in the TD Cowen 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Adverum to Participate in the Oppenheimer 34th Annual Life Sciences Conference
12 Feb 2024 //
GLOBENEWSWIRE
Adverum Announces Positive Safety Data from LUNA Phase 2 Trial of Ixo-vec
08 Feb 2024 //
GLOBENEWSWIRE
Adverum`s gene therapy reduces treatment burden in wet AMD
08 Feb 2024 //
FIERCE BIOTECH
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
05 Feb 2024 //
GLOBENEWSWIRE
Adverum will Host Webcast to Review LUNA Phase 2 Efficacy and Safety Results
01 Feb 2024 //
GLOBENEWSWIRE
Adverum Bio Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
29 Jan 2024 //
GLOBENEWSWIRE
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data
07 Dec 2023 //
GLOBENEWSWIRE
Adverum to Participate in the Evercore ISI 6th Annual HealthCONx Conference
28 Nov 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Adverum Bio Appoints C. David Nicholson, Ph.D. to its Board of Directors
06 Nov 2023 //
GLOBENEWSWIRE
Adverum Announces 3-Year Efficacy Results from the OPTIC Extension Study
04 Nov 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data
26 Sep 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies to Participate in Upcoming Investor Conferences
21 Sep 2023 //
GLOBENEWSWIRE
Adverum to Participate in the H.C. Wainwright 25th Annual Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
Adverum Bio Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
21 Aug 2023 //
GLOBENEWSWIRE
Adverum to Participate in H.C. Wainwright 3rd Ophthalmology Conference
14 Aug 2023 //
GLOBENEWSWIRE
Adverum Completes Enrollment of Phase 2 LUNA Trial in Wet AMD
10 Aug 2023 //
GLOBENEWSWIRE
Adverum Grants License to Ray Therapeutics for the AAV.7m8 Intravitreal Capsid
12 Jun 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces New Executive Leadership Roles
25 May 2023 //
GLOBENEWSWIRE
Adverum Presents Nonclinical Data in Support of Ixo-vec ASGCT
18 May 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program
18 May 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies to Participate in RBC Capital Markets Global Conference
10 May 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023
02 May 2023 //
GLOBENEWSWIRE
Adverum Presents Data at ARVO Supporting Bilateral Administration of Ixo-vec
23 Apr 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation
17 Apr 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies Reports 4Q & Full Reports 2022 FYR Ph2 LUNA Trial
30 Mar 2023 //
GLOBENEWSWIRE
Adverum Biotechnologies to Present at Upcoming Investor Conferences
27 Feb 2023 //
GLOBENEWSWIRE
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Jan 2023 //
GLOBENEWSWIRE
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 Dec 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Presents +VE End of Study Results from the OPTIC Trial
04 Nov 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Data Presentation The Retina Society
27 Oct 2022 //
ADVERUM
Adverum Presents Anatomical Improvements in Intraretinal and Subretinal
30 Sep 2022 //
GLOBENEWSWIRE
Adverum to Participate in the Chardan 6th Annual Genetic Medicines
27 Sep 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
23 Sep 2022 //
GLOBENEWSWIRE
Adverum to Participate in the Jefferies Cell and Genetic Medicine Summit
23 Sep 2022 //
GLOBENEWSWIRE
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Ph2
14 Sep 2022 //
GLOBENEWSWIRE
